查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2132346

老齡化黃斑部病變市場規模、佔有率和趨勢分析報告：按產品、疾病、分銷管道、地區和細分市場預測（2026-2033 年）

Age-related Macular Degeneration Market Size, Share & Trends Analysis Report By Product, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

老齡化黃斑部病變市場概述

全球老齡化黃斑部病變市場預計到 2025 年將達到 116 億美元，到 2026 年將成長到 125 億美元，到 2033 年將擴大到 227 億美元，2026 年至 2033 年的複合年成長率為 9.0%。

預計到2025年，北美市場將成為市場成長的主要驅動力，佔全球銷售額的53.9%。老齡化黃斑部病變（AMD）仍然是老年人不可逆性視力喪失的主要原因之一，而與老化相關的日益沉重的負擔正在推動市場成長。

推動眼科市場發展的因素包括：疾病認知度的提高、視網膜成像技術（如光學同調斷層掃描(OCT)）的進步以及眼科專科醫療服務覆蓋範圍的擴大，從而實現早期診斷和及時治療。抗血管內皮生長因子 (抗 VEGF) 療法仍然是新生血管性（濕性）老齡化黃斑部病變的標準治療方法，而補體通路抑制劑的引入則為乾性老齡化黃斑部病變中的地圖狀萎縮提供了更多治療選擇。持續的藥物緩釋系統、基因療法和新型生物製藥的研究與開發正在強化開發平臺，並致力於減輕患者的治療負擔。同時，醫療保健支出的成長、開發中國家視網膜醫療基礎設施的完善以及更多製藥和生物技術公司進軍眼科領域，都為已開發地區和新興地區的眼科市場穩步成長提供了支撐。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：老齡化相關性黃斑部病變市場：變數、趨勢和範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：老齡化相關性黃斑部病變市場：依產品進行業務分析

  • 按產品分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按產品分類，2021-2033 年
  • 艾里亞
  • Lucentis
  • Beovu
  • 其他

第5章：老齡化相關性黃斑部病變市場：疾病特異性業務分析

  • 按疾病分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按疾病分類，2021-2033 年
  • 濕性老齡化黃斑部病變（濕性AMD）
  • 乾性老齡化黃斑部病變（乾性AMD）

第6章：老齡化黃斑部病變市場：依分銷管道進行業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章：老齡化相關性黃斑部病變市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Novartis AG
    • Bayer AG
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bausch Health Companies Inc.
    • Regeneron Pharmaceuticals Inc.
    • Amgen Inc.
    • Biogen
    • Samsung Bioepis
Product Code: GVR-4-68039-971-3

Age-related Macular Degeneration Market Summary

The global age-related macular degeneration market size was valued at USD 11.6 billion in 2025 and is projected to grow from USD 12.5 billion in 2026 to USD 22.7 billion by 2033, at a CAGR of 9.0% from 2026 to 2033. The market in North America dominated with a revenue share of 53.9% in 2025. The market is driven by the increasing burden of the aging population, as AMD remains one of the leading causes of irreversible vision loss among older adults.

The market is supported by growing disease awareness, improvements in retinal imaging technologies such as optical coherence tomography (OCT), and broader access to specialist ophthalmology services, enabling earlier diagnosis and timely treatment. Anti-vascular endothelial growth factor (anti-VEGF) therapies remain the standard of care for neovascular (wet) AMD, while the introduction of complement pathway inhibitors has expanded treatment options for geographic atrophy in dry AMD. Ongoing research in sustained-release drug delivery systems, gene therapies, and novel biologics is strengthening the development pipeline and addressing the need to reduce treatment burden. At the same time, increasing healthcare expenditure, expanding retinal care infrastructure in developing countries, and the growing involvement of pharmaceutical and biotechnology companies in ophthalmology are supporting steady market growth across both developed and emerging regions.

Global Age-related Macular Degeneration Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Age-related macular degeneration market report based on product, disease, distribution channel, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Eylea
  • Lucentis
  • Beovu
  • Others
  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • Wet AMD
  • Dry AMD
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Age-related Macular Degeneration Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Age-related Macular Degeneration Market: Product Business Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Billion)
  • 4.4. Eylea
    • 4.4.1. Eylea Market, 2021 - 2033 (USD Billion)
  • 4.5. Lucentis
    • 4.5.1. Lucentis Market, 2021 - 2033 (USD Billion)
  • 4.6. Beovu
    • 4.6.1. Beovu Market, 2021 - 2033 (USD Billion)
  • 4.7. Others
    • 4.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. Age-related Macular Degeneration Market: Disease Business Analysis

  • 5.1. Disease Market Share, 2025 & 2033
  • 5.2. Disease Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Billion)
  • 5.4. Wet AMD
    • 5.4.1. Wet AMD Market, 2021 - 2033 (USD Billion)
  • 5.5. Dry AMD
    • 5.5.1. Dry AMD Market, 2021 - 2033 (USD Billion)

Chapter 6. Age-related Macular Degeneration Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2025 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Billion)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Billion)
  • 6.6. Online Pharmacy
    • 6.6.1. Online Pharmacy Market, 2021 - 2033 (USD Billion)

Chapter 7. Age-related Macular Degeneration Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Age-related Macular Degeneration Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Novartis AG
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Bayer AG
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Pfizer Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. F. Hoffmann-La Roche Ltd.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Bausch Health Companies Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Regeneron Pharmaceuticals Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Amgen Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Biogen
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Samsung Bioepis
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Age-related macular degeneration market, by region, 2021 - 2033 (USD Billion)
  • Table 4. Global Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 5. Global Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 6. Global Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 7. North America Age-related macular degeneration market, by country, 2021 - 2033 (USD Billion)
  • Table 8. North America Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 9. North America Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 10. North America Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 11. U.S. Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 12. U.S. Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 13. U.S. Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 14. Canada Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 15. Canada Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 16. Canada Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 17. Mexico Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 18. Mexico Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 19. Mexico Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 20. Europe Age-related macular degeneration market, by country, 2021 - 2033 (USD Billion)
  • Table 21. Europe Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 22. Europe Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 23. Europe Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 24. UK Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 25. UK Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 26. UK Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 27. Germany Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 28. Germany Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 29. Germany Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 30. France Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 31. France Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 32. France Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 33. Italy Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 34. Italy Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 35. Italy Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 36. Spain Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 37. Spain Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 38. Spain Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 39. Norway Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 40. Norway Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 41. Norway Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 42. Denmark Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 43. Denmark Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 44. Denmark Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 45. Sweden Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 46. Sweden Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 47. Sweden Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 48. Asia Pacific Age-related macular degeneration market, by country, 2021 - 2033 (USD Billion)
  • Table 49. Asia Pacific Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 50. Asia Pacific Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 51. Asia Pacific Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 52. Japan Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 53. Japan Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 54. Japan Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 55. China Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 56. China Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 57. China Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 58. India Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 59. India Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 60. India Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 61. Australia Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 62. Australia Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 63. Australia Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 64. South Korea Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 65. South Korea Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 66. South Korea Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 67. Thailand Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 68. Thailand Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 69. Thailand Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 70. Latin America Age-related macular degeneration market, by country, 2021 - 2033 (USD Billion)
  • Table 71. Latin America Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 72. Latin America Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 73. Latin America Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 74. Brazil Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 75. Brazil Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 76. Brazil Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 77. Argentina Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 78. Argentina Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 79. Argentina Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 80. Middle East & Africa Age-related macular degeneration market, by country, 2021 - 2033 (USD Billion)
  • Table 81. Middle East & Africa Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 82. Middle East & Africa Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 83. Middle East & Africa Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 84. South Africa Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 85. South Africa Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 86. South Africa Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 87. Saudi Arabia Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 88. Saudi Arabia Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 89. Saudi Arabia Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 90. UAE Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 91. UAE Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 92. UAE Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 93. Kuwait Age-related macular degeneration market, by product, 2021 - 2033 (USD Billion)
  • Table 94. Kuwait Age-related macular degeneration market, by disease, 2021 - 2033 (USD Billion)
  • Table 95. Kuwait Age-related macular degeneration market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Age-related macular degeneration market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Age-related macular degeneration market dynamics
  • Fig. 11 Age-related macular degeneration market: Porter's five forces analysis
  • Fig. 12 Age-related macular degeneration market: PESTLE analysis
  • Fig. 13 Product market, 2021 - 2033 (USD Billion)
  • Fig. 14 Eylea market, 2021 - 2033 (USD Billion)
  • Fig. 15 Lucentis market, 2021 - 2033 (USD Billion)
  • Fig. 16 Beovu market, 2021 - 2033 (USD Billion)
  • Fig. 17 Others market, 2021 - 2033 (USD Billion)
  • Fig. 18 Disease market, 2021 - 2033 (USD Billion)
  • Fig. 19 Wet AMD market, 2021 - 2033 (USD Billion)
  • Fig. 20 Dry AMD market, 2021 - 2033 (USD Billion)
  • Fig. 21 Distribution channel market, 2021 - 2033 (USD Billion)
  • Fig. 22 Hospital Pharmacy market, 2021 - 2033 (USD Billion)
  • Fig. 23 Retail Pharmacy market, 2021 - 2033 (USD Billion)
  • Fig. 24 Online pharmacy market, 2021 - 2033 (USD Billion)
  • Fig. 25 Age-related macular degeneration market revenue, by region
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 34 Europe Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 39 France country dynamics
  • Fig. 40 France Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 45 Norway country dynamics
  • Fig. 46 Norway Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 49 Denmark country dynamics
  • Fig. 50 Denmark Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 51 Asia Pacific Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 54 China country dynamics
  • Fig. 55 China Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 56 India country dynamics
  • Fig. 57 India Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 58 Australia country dynamics
  • Fig. 59 Australia Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 64 Latin America Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 69 MEA Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 76 Kuwait country dynamics
  • Fig. 77 Kuwait Age-related macular degeneration market, 2021 - 2033 (USD Billion)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework